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Abstract: Neovascularization provides the route for nutrient supply to the tumor and the conduit for tumor cells to be 
shed into the circulation. CD31 is a pan-endothelial cell marker and CD105 is an active endothelial cell marker, but 
whether there is a link between CD105 expression and metastasis in Hepatocellular carcinoma (HCC) still remains un-
clear. A tissue microarray containing 38 HCCs and adjacent non-tumorous liver tissue samples was constructed. The mi-
crovessel density (MVD) of CD31, CD105, vWF and the expression of PCNA, VEGF were investigated in a HCC tissue 
microarray by immunohistochemistry. There was a significant difference between the score of MVD-CD31 in HCC (48.5 
± 29.7) and non-tumorous liver tissue (24.2 ± 22.3, P<0.01). The mean score of MVD-CD31 was higher in HCCs with 
high PCNA expression (68.4 ± 37.0) than in HCCs with low PCNA expression (37.9 ± 30.9, P = 0.012). MVD-CD105 
and VEGF expression were significantly higher in HCC with intrahepatic metastasis (P < 0.01). Multivariate analysis con-
firmed that MVD- CD105 but not MVD-CD31 was an independent contributing factor to the intrahepatic metastasis. In 
conlusions, MVD-CD105 expression is associated with intrahepatic metastasis of HCC. Because CD105 is expressed in 
the activated endothelial cells of the newly formed blood vessels, neovascularization is important in the metastasis of 
HCC. 
INTRODUCTION 
 Hepatocellular carcinoma (HCC) is one of the most 
common cancers and is one of the leading causes of cancer 
death in Japan [1]. It is a tumor characterized by a propensity 
for vascular invasion and a high metastatic potential [2]. An-
giogenesis is a prerequisite for tumor growth and metastasis 
[3]. Neovascularization provides not only the route for nutri-
ent supply to the tumor but also the conduit for tumor cells to 
be shed into the circulation [4].
 
Newly formed capillaries 
have leaky basement membranes, making them more acces-
sible to tumor cells than mature vessels. It has been demon-
strated that increasing density of newly proliferating mi-
crovessels in growing tumors was correlated closely with 
increasing number of tumor cells shed into the bloodstream 
[5]. CD105 (endoglin) is a component of the transforming 
growth factor beta (TGF-) receptor complex as it binds 
TGF-1 and TGF-3 with high affinity. CD105 has been 
reported as expressed by endothelial cells of proliferating 
capillaries [6]. However there are few reports on the expres-
sion of CD105 in hepatocellular carcinoma [7, 8]. The ex-
pression pattern of CD105 and a link between CD105 ex-
pressing capillaries and metastasis in HCC still remain un-
clear. Tissue microarray is a method which can detect the 
protein expression of a large number of samples simultane-
ously [9].
 
Therefore, we conducted a prospective study using 
 
 
*Address correspondence to this author at the Department of Pathology and 
Biodefense, Faculty of Medicine, Saga University, Saga 849-8501, Japan; 
Tel: 81-952-34-2230; Fax: 81-952-34-2055;  
E-mail: tokunao@cc.saga-u.ac.jp 
tissue microarray methodology to evaluate the expression of 
CD105 in 38 resected HCCs. 
MATERIALS AND METHODS 
Patients and Tissue Samples 
 Thirty eight patients with curative resection of HCC were 
recruited into this prospective study at Saga University Hos-
pital from 1999 to 2004 under the guideline of the Ethical 
Committee for Human Study, Saga University School of 
Medicine. The average age of patients was 64 years, ranging 
in age from 43 to 82 years. There were 7 women and 31 
men. The average tumor size was 6.6 cm with 13 tumors less 
than 3 cm. Among the 38 patients with HCC, 27 had hepati-
tis C infection and 6 had hepatitis B infection. The fresh tis-
sue specimens were fixed in 10% buffered formalin and em-
bedded in paraffin. Intrahepatic metastasis (IM) was diag-
nosed as follows: near the main tumor, much smaller than 
main tumor and with the same histology type as the main 
tumor. During this study, we found that the number of surgi-
cally resected HCC cases larger than 3 cm in diameter was 
small and we added further 24 cases to match the number of 
HCC with large size for comparison by courtesy of our af-
filiated hospital Koseikan.  
Construction of Tissue Microarrays of HCC 
 Tissue microarray was constructed using a Tissue Ar-
rayer (Beecher Instruments Inc., Sun Prairie, WI, USA), 
providing microsections of 2 mm in diameter (Fig. 1). The 
appropriate tumor areas were selected on HE paraffin sec-
tions. Three areas which were located in the central and pe-
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ripheral part of the cancer, and non-cancerous liver tissue 
were selected in each sample. Cores were punched out from 
donor blocks and placed in recipient blocks. An array block 
of 119 cores was derived from normal liver tissue (n = 5), 
center part of the cancer (n = 38), peripheral part of the can-
cer (n = 38) and non-cancerous liver tissue (n = 38). The 
array blocks were then incubated for 30 min at 37°C to im-
prove adhesion between the cores and the recipient paraffin 
block. Immunohistochemical studies were performed on 
4μm-thick paraffin sections.  
Double-Immunofluorescence Staining 
 Double-immunofluorescence staining was performed 
following a previously reported method [10].
 
Briefly, the 
tissue array slides were deparaffinized and soaked in 0.01 M 
citrate buffer, pH 6.0, at 90°C for 40 min for antigen re-
trieval. The primary murine monoclonal antibody CD31, and 
then rhodamine-labeled secondary rabbit polyclonal anti-
body against murine IgG were allowed to react. After inacti-
vation of the first step of primary and secondary antibodies 
by heating at 90°C for 15 min in citrated buffer, the second 
immunoreaction was carried out with another primary mur-
ine monoclonal antibody, CD68, and then with FITC-labeled 
secondary rabbit polyclonal antibody. Rhodamine and FITC-
labeled samples were examined using a fluorescence micro-
scope (Olympus BX60, Tokyo, Japan). To detect nonspe-
cific-antibody binding, control sections were incubated with 
either normal murine or rabbit serum or phosphate-buffered 
saline instead of primary antibody. No staining was observed 
in these control samples. 
Immunohistochemical Staining 
 Sections of tissue microarray were immunostained with 
human CD105, CD31, von Willebrand factor (vWF), prolif-
erating cell nuclear antigen (PCNA), vascular endothelial 
growth factor (VEGF) monoclonal antibodies, respectively. 
Table 1 showed the details of antibody used in this research. 
The tissue sections were dewaxed, soaked in PBS (pH7.2), 
and then treated with 10% hydrogen peroxide to block en-
dogenous peroxidase activity. Antigen retrieval was per-
formed following a previously reported method [10]. The 
tissue microarray sections were then incubated with primary 
antibodies at 4°C over night. The negative control was ob-
tained by substituting the primary antibodies for PBS. Inten-
sity of immunostaining for CD31, CD105 and vWF was as-
sessed at 200 magnification. The number of microvessels 
was counted from three areas and was expressed as mi-
crovessel density (MVD) on the average. 
Table 1. Antibodies and Antigen Retrieval Methods  
 
Antibody Clone Pretreatment  Dilution Company 
CD31 Mono Proteinase K  1:20 Dako 
CD105 Mono MW-EDTA  1:50 Novocastra 
vWF Mono Proteinase K  1:100 Dako 
VEGF Mono MW-AC  1:100 Santa Cruz 
PCNA Mono MW-EDTA  1:50 Dako 
Antigen retrieval method for immunohistochemistry: MW:microwave, 
AC:citrate buffer, For immunofluorescence, see Materials and Methods. 
 
 The rate of PCNA-positive cancer cells was defined as 
the positively stained nuclei to the total cell count. The posi-
tive nuclei less than 1% was evaluated as 0, 1-20% evaluated 
as 1, 21-50% evaluated as 2, over 50% evaluated as 3. We 
regarded 2 and 3 as high expression of PCNA. The judgment 
of VEGF staining was adopted as the proper immunohisto-
chemical score of the HCC on the basis of strength: 0, nega-
tive; 1, weak staining; 2, moderarate staining; 3, strong stain-
ing. We regarded 1-3 as positive VEGF staining. In this 
study, the staining pattern of VEGF was diffuse.  
 All of the immunostaining scores were calculated by two 
pathologists in a blinded manner. 
Statistical Analysis 
 The clinical and pathologic characteristics of the patients 
in relation to MVD of CD105, CD31, vWF and the expres-
sion of VEGF, PCNA were compared by the student's t test 
and x
2
 test. SYSTAT 10.2 (Systat Software Inc., Chicago, 
 
Fig. (1). The tissue microarray of HCC. (A) Slide of H.E. staining. (B-E) Representative tissue samples. (B) HCC. (C) Transitional zone of 
HCC. (D) Chronic hepatitis. (E) Cirrhosis. 
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IL, USA) was used. The P value of less than 0.05 was con-
sidered to be significant. For Multivariate analysis, JMP Sta-
tistics program (SAS Institute, Cary, NC, USA) was used. 
RESULTS 
The Expression Pattern of CD31, vWF, CD105, PCNA 
and VEGF in HCC and Non-Tumorous Liver  
 CD31 was universally expressed in endothelial cells of 
newly formed sinusoid in HCC (Fig. 2A). In non-tumorous 
liver tissues, which were normalcirrhotic or associated 
with chronic hepatitis, there was a limited staining at the 
portal area in the normal liver, and a sparse staining in the 
latter two (Fig. 2B).  
 The pattern of staining by anti-vWF was different from 
that by anti-CD31, with staining of mainly larger vessels in 
the fibrous tissue within the tumor, rather than the capillary-
like sinuoids between cancer cells (Fig. 3A). CD105 was 
also expressed in endothelial cells of newly formed sinusoids 
in HCC (Fig. 3B). PCNA was expressed in the nuclei (Fig. 
3C). VEGF was expressed mainly in the cytoplasm of HCC 
and non-tumorous liver tissues (Fig. 3D). 
 
Fig. (2). CD31 expression in HCC and non-HCC liver tissue. (A) CD31 (red) was observed in endothelial cells of newly formed sinusoid in 
HCC. (B) CD31 was only positive in the vascular endothelial cells in portal area in non-HCC liver tissue. Green: CD68 positive kupffer's 
cells. x200. 
 
Fig. (3). The vWF, CD105, PCNA, and VEGF expression in HCC. (A) The vWF expression was observed in endothelial cells of larger ves-
sels in the fibrous tissue of tumor. (B) CD105 expression was observed in endothelial cells of newly formed sinusoids in HCC. (C) PCNA 
expression was seen in nuclei of HCC cell. (D) VEGF expression was observed in HCC cell cytoplasm in a diffuse staining pattern. x200. 
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MVD in HCC and Non-Tumorous Liver 
 The mean score of MVD-CD31 was 48.5 ± 29.7 in HCC, 
whereas the mean score of MVD-CD31 was 24.2 ± 22.3 in 
non-tumorous liver tissue (Fig. 4). There was a significant 
difference between the score of MVD-CD31 in HCC and 
non-tumorous liver tissue (P < 0.01). The mean score of 
MVD-CD31 was higher in HCC with high PCNA expression 
(68.4 ± 37.0) than in HCCs with low PCNA expression (37.9 
± 30.9, P = 0.012) (Fig. 5).  
 
Fig. (4). Comparison of MVD in HCC and non-tumorous liver 
tissue. There was a significant difference on the score of MVD-
CD31 between HCC and non-tumorous liver tissue(* P<0.01). But 
there was no significant difference on the score of MVD-105 or 
vWF between HCC and non-tumorous liver tissue. 
 
Fig. (5). The relationship between MVD-CD31, -CD105, and -vWF 
and the expression of PCNA in HCC. The mean score of MVD-
CD31 was higher in HCCs with high PCNA expression than with 
low PCNA expression. * P=0.012. There was no significant differ-
ence between the score of CD105 and vWF. 
 The MVD-CD105 was significantly lower than MVD-
CD31 in the same tissue. There was a diffuse staining pattern 
of CD105 in adjacent non-tumorous livers in some speci-
mens. There was no significant difference between the score 
of MVD-105 or vWF in HCC and non-tumorous liver tissue.  
Correlation Between MVD and Expression of PCNA and 
VEGF and Clinicopathological Parameters 
 The analysis of MVD-CD31, MVD-CD105, MVD-vWF 
in relation to various clinicopathological parameters is sum-
marized in Table 2. Significantly higher MVD-CD105 was 
only associated with HCC with intrahepatic metastasis (IM) 
(p < 0.01). Multivariate analysis showed that a high MVD- 
CD105 was a significant (p = 0.0214) and independent con-
tributing factor to intrahepatic metastasis (IM, Table 3). Fur-
thermore, in large HCCs (> 3cm) with IM, the MVD-CD105 
was 27.09 ± 18.35, while in large HCCs without IM, the 
MVD-CD105 was 7.27 ± 6.07. It revealed that CD105 was 
significantly stronger expressed in HCC with IM even in 
large tumours (Fig. 6). No significant differences, however, 
were found between MVD-CD31 or MVD-vWF and each 
clinicopathological parameter such as gender, tumor size, 
venous invasion and IM. 
Table 2. Relationship Between MVD of CD105, CD31, vWF 
and Clinicopathological Parameters in HCCs 
 
Positive Microvessel Density 
Variable 
 MVD-CD105  MVD-CD31  MVD-vWF 
Sex 
 Male(n=31) 14.6±12.5  56.5±35.5 22.6±11.7 
Female(n=7) 32.0±26.9  32.0±36.6 16.8±14.2 
Tumor Size 
 3 cm(n=13) 14.4±12.5  65.3±32.0 22.8±8.0  
 >3 cm(n=25) 19.3±18.7  49.6±37.1 21.5±13.5 
Histology Type 
 Well(n=7) 15.1±14.9  45.2±32.3 14.8±10.7 
 Moderate(n=27) 15.9±14.1  56.8±39.2 22.4±12.6 
 Poor(n=4) 35.5±14.1  34.8±7.8  26.8± 8.3 
IM 
With (n=14) 26.8±19.8* 66.6±39.4 25.2±15.2 
Without (n=24) 11.9±11.1*  44.9±32.9 19.7±9.9  
Vascular Invasion 
 With(n=18)  18.2±17.4  54.7±39.8 22.7±15.4 
 Without(n=20) 17.4±17.3  50.5±33.7 20.6±8.2  
*P < 0.01. 
IM:Intrahepatic metastasis (IM). 
 
 There was no significant difference in the intensity of 
VEGF expression between the HCC cells and the non-
tumorous liver cells. However, VEGF was expressed in 
92.3% (12/13) of HCCs with IM and in 45.8% (11/24) of 
HCCs without IM. VEGF expression was significantly 
higher in HCC with IM (p < 0.01). 
* p-value between groups <0.01 
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Fig. (6). MVD-CD105 in large HCCs (> 3cm) with or without in-
trahepatic metastasis (IM).  MVD-CD105 is significantly higher in 
HCC with IM than those without IM. 
*
P = 0.0214. Twenty five 
HCC cases larger than 3cm were combined with 24 those cases 
from Koseikan Hospital. 
Table 3. Multivariate Analysis of the Contributing Factors to 
the Intrahepatic Metastasis 
 
Factor F P Value 
Diameter 2.07 0.5584 
Histology type 1.51 0.9590 
Capsule invasion 5.28 0.1527 
Venous invasion 2.15 0.9889 
MVD-CD105 9.69 0.0214 
MVD-CD31 2.21 0.5291 
Age 4.68 0.1964 
MVD: microvessel density. 
 
DISCUSSION 
 The growth and metastasis of solid tumors are dependent 
on the formation of new blood vessels [11]. Angiogenesis is 
closely associated with the cancer development and facili-
tates tumor progression and metastasis [12]. Different from 
that in normal physiological condition, the balance of pro-
angiogenesis and anti-angiogenesis is disturbed in tumor 
microenvironment, thus leading to abnormal vessel growth. 
Intratumoral microvessel density (IMVD) has been exten-
sively investigated and found to be a useful prognostic 
marker in many cancers [13-15]. CD31 is a pan-endothelial 
cell marker, which is expressed in both of immature tumor 
blood vessels and mature blood vessels [16]. IMVD-CD31 
may reflect the exact number of tumor blood vessels than 
other endothelial cell marker. We found that the mean score 
of MVD-CD31 in HCC was markedly higher than that in 
non-tumorous liver tissue. The frequency of MVD was in 
accordance with the results of previous studies on HCC [17]. 
And in non-tumorous liver, CD31 positive vessels existed on 
portal canal area. There was also a significant difference in  
 
the score of MVD-CD31 between HCC with different PCNA 
expression. These results suggested that increased angio-
genesis prompted the proliferation of HCC, which might be 
related to the carcinogenesis of HCC. 
 Metastasis is the most lethal attribute of malignant tu-
mors. HCC often gives rise to IM, which would lead to fail-
ure of the cure. CD105 is a homodimeric membrane glyco-
protein expressed on endothelial cells that can bind to TGF-
1 and -3. It is only expressed on active endothelial cells 
and consequently be able to reflect a neoangiogenesis in ma-
lignant tumors [10, 18]. Neovascularization provides not 
only the route for nutrient supply to the tumor but also the 
conduit for tumor cells to be shed into the circulation be-
cause newly formed vessels are often absent of basement 
membrane [19]. Recent research has shown that CD105 is 
only weakly expressed in normal tissues, but it is strongly 
expressed in tumor endothelial cells [10, 20, 21]. CD105 has 
been demonstrated to be a good tumor angiogenesis marker 
in breast cancer
 
[22], colorectal cancer [10, 23] and mela-
noma [24]. Higher expression and the superiority of CD105 
over CD31 in active angiogenesis in HCC were recognized 
by many investigators [7, 8, 25, 26], but there are controver-
sial opinions about its specificity in that the higher expres-
sion was not only present in microvessels in HCC but also in 
hepatic sinus endothelium in non-tumorous tissue with or 
without cirrhosis [26]. CD105 expression as a prognostic 
indicator is also controversial in microvessels of HCC [7, 8]. 
Benetti reported that TGF-1 promotes the migration of 
CD105 expressing HCC-derived endothelium [27]. But the 
direct link between CD105 expression and IM still remains 
unclear; we found that CD105 expression was higher in 
HCCs with IM than those without IM. Multivariate analysis 
showed that a high MVD-CD105 was a significant and inde-
pendent contributing factor to intrahepatic metastasis. And 
CD105 was significantly expressed stronger in HCC with IM 
even in same size tumors. In our knowledge, we reported the 
close relationship between MVD-CD105 and IM for the first 
time. These results suggested that neovascularization might 
promote IM in HCC. Interestingly, we found a diffuse stain-
ing of CD105 in non-tumorous livers adjacent to HCC, 
which was previously reported [26]. It was not surprising 
because most of the HCC patients in this study were infected 
with hepatitis C virus (27/38) or B virus (6/38), which leads 
to chronic hepatitis or cirrhosis. The state of virus infection 
will induce a biological activity to the liver cell and enhance 
the CD105 expression.  
 Among the angiogenesis factors, VEGF is the most im-
portant one and a hot field of the study at present. A high 
serum level of VEGF is a predictor of poor outcome after 
resection of HCC [28]. We found that VEGF was expressed 
in 92.3% (12/13) of HCCs with IM and in 45.8% (11/24) of 
HCCs without IM. This result suggested that up-regulation 
of VEGF was related to IM of HCC.  
 In conclusion, we detected the MVD of CD31, CD105, 
vWF and the expression of PCNA, VEGF using a HCC tis-
sue microarray. A higher MVD-CD105 was associated with 
IM of HCC. As CD105 is expressed on new blood vessels, 
neovascularization might be important in the metastasis of 
HCC. Further studies are needed to clarify the mechanisms. 
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